International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-4 doi: 10.5281/zenodo.13221041
Original Research Article
Awareness about Sickle Cell Disorders amongst the Population in Central India – A Cross Sectional Study
Published
Aug. 5, 2024
Abstract

Introduction:Sickle Cell Disorder (SCD), marked by abnormal haemoglobin Hb S, causes rigid, sickle-shaped erythrocytes, blocking circulation and leading to multiorgan damage. Globally, over 3,00,000 infants are born with SCD every year, with India ranking second in prevalence, affecting 20 million people. While advanced nations benefit from neonatal screenings and immunization, low-income regions, including rural India, face high childhood mortality rates (50-80%). Lack of awareness, delayed diagnosis, and inadequate management contribute to elevated mortality, particularly in less-educated rural and tribal areas. This study aims to evaluate public awareness of SCD to address the pressing issue in India. Material and Methods: This was a cross-sectional study of both known cases of Sickle Cell Disorder (SCD) and non-SCD individuals. A total of 169 consenting individuals were interviewed using a structured validated questionnaire. Results: We observed lack of awareness regarding Sickle Cell Disorders (SCD) in 40% of the participants, while 60% were found to be aware of its existence. Conclusion: The study reveals a notable lack of awareness about Sickle Cell Disorder (SCD), including its causes, diagnosis, and treatment. Given the substantial contribution of central India to annual SCD cases, addressing these awareness gaps is imperative. Targeted educational efforts, screenings and awareness campaigns are vital to bridging this knowledge deficit and improving outcomes in the region.

Recommended Articles
Loading Image...
Volume-5, Issue-4
Citations
913 Views
299 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved